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Abstract 
Background: Human T cell leukemia virus type 1 (HTLV-1) basic leucine zipper factor (HBZ), which is encoded by a 
minus strand mRNA, is thought to play important roles in the development of adult T-cell leukemia (ATL) and HTLV-
1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). However, a comprehensive analysis of HBZ, includ-
ing mRNA and protein expression, humoral immunoreactivity against HBZ, and HTLV-1 proviral load (PVL), in HTLV-
1-infected individuals with different clinical status has not been reported previously.
Results: In this study, using novel monoclonal antibody-based in-house enzyme-linked immunosorbent assay sys-
tems, we report the absolute quantification of HBZ protein and its plasma antibody in clinical samples from HTLV-1-in-
fected individuals with different clinical status. The data were compared to both HBZ mRNA levels and PVL. The results 
showed that plasma anti-HBZ antibody was detectable only in 10.4 % (5/48) of asymptomatic carriers (ACs), 10.8 % 
(13/120) of HAM/TSP patients, and 16.7 % (7/42) of ATL patients. HBZ protein was detected in three out of five patients 
with acute ATL, but was not detected in patients with HAM/TSP (0/10) or ACs (0/4). Thus, an antibody response to HBZ 
was not associated with the PVL or the expression of HBZ (both at the mRNA and protein levels) or the clinical status 
of the infection.
Conclusions: The present results emphasize the extremely low expression and immunogenicity of HBZ in natural 
HTLV-1 infection. However, there is a possibility that the low but distinct expression of HBZ protein in PBMCs is associ-
ated with the survival of HTLV-1-infected cells and the development of ATL.
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Background
Human T cell leukemia virus type-1 (HTLV-1) has been 
linked to the development of adult T-cell leukemia (ATL) 
[1, 2] and a chronic inflammatory disease called HTLV-
1-associated myelopathy/tropical spastic paraparesis 
(HAM/TSP) [3, 4]. HTLV-1 bZIP factor (HBZ) is a viral 
transcriptional regulator encoded in the minus strand 
of the 3ʹ-terminal region of the HTLV-1 genome [5]. 
HBZ is thought to play important roles in the pathogen-
esis of HTLV-1 associated diseases, because HBZ is the 
only viral gene that is genetically highly conserved [6], 
its mRNA is constitutively and ubiquitously expressed 
by all ATL cells and supports their proliferation [7], its 
mRNA expression is correlated with the HTLV-1 pro-
viral load (PVL) and disease severity of HAM/TSP [8], 
its expression enhances the proliferative capacity of 
HTLV-1 infected T cells in culture and a transplantation 
model [9], and transgenic expression of HBZ in CD4+ 
T cells induced both T-cell lymphomas and systemic 
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inflammation in mice [10]. The coding sequence of HBZ 
does not overlap with that of another viral transcription 
factor, Tax, which is also crucial for HTLV-1-mediated 
transformation, and HBZ acts in an manner opposite to 
Tax in the regulation of many viral and host genes [11, 
12]. From an immunological perspective, HBZ differs sig-
nificantly from other HTLV-1 proteins. A recent in silico 
analysis showed that strong binding of HBZ peptides 
[13], but not Tax peptides [which are immunodominant 
for circulating HTLV-1-specific cytotoxic T lymphocytes 
(CTLs)], to HLA class 1 molecules was associated with 
lower PVL and a reduced risk of developing HAM/TSP 
[13]. The predicted binding affinity of HLA to HBZ pep-
tides was significantly weaker than that to the Tax pep-
tides, and the detection frequency of HBZ-specific CTLs 
in HTLV-1-infected individuals was significantly lower 
than that of Tax-specific CTLs [14]. These observations 
suggest that efficient control of viral replication is associ-
ated with CTL recognition of poorly immunogenic HBZ 
protein, but not the immunodominant Tax protein [13], 
and that a strong immune response to HBZ is associated 
with a low PVL, which reduces the risk of both HAM/
TSP [15] and ATL [16].
A previous in  vitro study demonstrated that although 
high-avidity CTL lines against HBZ can be generated 
despite its poor immunogenicity [17], these CTL lines 
were able to lyse an autologous B-lymphoblastoid cell 
line (B-LCL) loaded with HBZ peptide, but not freshly 
isolated ATL cells [17]. More importantly, it was recently 
reported that recombinant vaccinia viruses express-
ing HBZ (rVV-HBZ) induce the production of CTLs 
in vivo that exert an anti-lymphoma effect in mouse and 
macaque models of ATL [18]. Specifically, vaccination 
with rVV-HBZ elicited specific T-cell responses in both 
mice and rhesus macaques. Furthermore, adoptive trans-
fer of splenocytes obtained from rVV-HBZ-vaccinated 
mice significantly improved the survival of HBZ-express-
ing lymphoma cell-inoculated mice [18]. This study 
clearly demonstrates the importance of the HBZ protein 
and the potential of HBZ as a target antigen for immu-
notherapy of ATL [19]. Therefore, to develop preventive 
and therapeutic approaches for HTLV-1-associated dis-
eases, it is important to examine the roles of HBZ and 
its immunological properties using clinical samples from 
HTLV-1-infected individuals with different clinical sta-
tus. However, to date, there is no comprehensive analysis 
of HBZ with multiple parameters, including mRNA, pro-
tein, and anti-HBZ antibody levels and HTLV-1 PVL, in 
naturally infected cells from HTLV-1-infected individu-
als. In this study, we generated novel anti-HBZ monoclo-
nal antibodies (mAbs) and developed an enzyme-linked 
immunosorbent assay (ELISA) to detect and quantify 
both HBZ protein and anti-HBZ antibody levels in clini-




Peripheral blood was obtained from 120 patients with 
a clinical diagnosis of HAM/TSP, 42 ATL patients, 48 
asymptomatic carriers (ACs), and 17 uninfected nor-
mal controls (NCs). The clinical profiles of the HTLV-
1-infected individuals that participated in this study are 
shown in Table 1. Diagnosis of HAM/TSP and ATL was 
based on the World Health Organization diagnostic cri-
teria [20] and Shimoyama criteria [21], respectively. This 
study was approved by the Research Ethics Committee of 
Kawasaki Medical School under the approval number of 
1422-2, and written informed consent was obtained from 
all study subjects. Fresh peripheral blood mononuclear 
cells (PBMCs) were isolated by Histopaque-1077 (Sigma, 
St. Louis, MO) density gradient centrifugation, washed 
twice in RPMI 1640 with 10 % fetal calf serum (FCS), and 
stored in liquid nitrogen as stock lymphocytes until use. 
Plasma samples were stored at −80  °C until use. Seven 
HTLV-1-infected T-cell lines (C5/MJ, HUT-102, MT-1, 
MT-2, MT-4, SLB-1, TLOm1) and three HTLV-1-un-
infected T-cell lines (CEM, Jurkat, MOLT-4) were used 
in this study. These cells were cultured in RPMI 1640 
medium supplemented with 10  % heat inactivated FCS, 
50 U/mL penicillin, and 50 µg/mL streptomycin (Wako, 
Osaka, Japan) at 37 °C in 5 % CO2.
Table 1 Clinical profiles of HTLV-1 infected individuals participated in this study
The results represent the mean ± SD
a HTLV-1 Tax copy number per 104 PBMCs
ACs (n = 48) HAM/TSP (n = 120) ATL (n = 42)
Age 51.7 ± 18.3 61.4 ± 12.8 65.0 ± 13.5
Sex [n (%)]
 Male 17 (35.4) 34 (28.3) 21 (50.0)
 Female 31 (64.6) 86 (71.7) 21 (50.0)
HTLV-1a proviral load (median) 713.8 ± 1300.0 (323.0) 865.6 ± 883.4 (620.0) 7359.5 ± 5705.2 (6710.5)
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Production of mAbs
To produce anti-HBZ mAbs, C57BL/6 mice or WKAH 
rats were immunized three or four times at 2-week 
intervals with keyhole limpet hemocyanin (KLH)-con-
jugated peptide fragments of HBZ (i.e., Peptides #1, #2, 
and #3; Additional file 1: Figure S1A) or histidine-tagged 
recombinant HBZ, which was produced in a wheat germ 
extract-based cell-free transcription and translation sys-
tem (WEPRO7240H Expression kit; CellFree Sciences, 
Japan) (Additional file  1: Figure S1B). It is important 
to note that hbz gene is the only HTLV-1 gene with no 
nonsense mutation and it is genetically highly con-
served among isolates, since human APOBEC3G gen-
erates nonsense mutations in the plus-strand coding 
sequence of HTLV-1 proviral genomes in vivo, targeting 
the minus strand of HTLV-1 during reverse transcrip-
tion [6]. After the booster immunization, mouse or rat 
spleen cells were isolated and fused with mouse myeloma 
cells (Sp2/0-Ag14) using 50  % polyethylene glycol 2000 
(Merck, Darmstadt, Germany). After selection in hypox-
anthine–aminopterin–thymidine (HAT) medium, cells 
were cloned by limiting dilution (1 cell per well) with BM 
Condimed H1 (Roche, Indianapolis, IN), at least twice to 
ensure monoclonality. Individual clones growing in par-
ticular wells were tested by ELISA with the immunizing 
antigens.
Transient transfection
The 293T cells were maintained in Dulbecco’s modified 
Eagle’s medium (Sigma, St Louis, MO) containing 10  % 
heat-inactivated FCS with 100  U/mL penicillin, 100  μg/
mL streptomycin sulfate, and 2 mM l-glutamine. The HBZ 
expression plasmids were constructed as follows. First, 
the spliced isoform of HBZ, which is the most abundant 
HBZ transcript and significantly contributes to HBZ pro-
tein synthesis [22–24], was amplified from cDNA derived 
from the PBMCs of HAM/TSP patients by RT-PCR using 
the following primers: HBZ-F, 5ʹ-ATG GCG GCC TCA 
GGG CTG-3ʹ and HBZ-R, 5ʹ-TTA TTG CAA CCA CAT 
CGC CTC-3ʹ. Then, the amplified fragment was cloned 
into the pCMV-HA mammalian expression vector con-
taining an N-terminal hemagglutinin (HA) epitope tag 
(Clontech Laboratories, Inc., Mountain View, CA). The 
1 µg of pCMV-HA-HBZ vector was transiently transfected 
into 5.0 × 105 293T cells by Lipofectamine LTX with PLUS 
Reagent (Invitrogen, Carlsbad, CA) according to the man-
ufacturer’s protocol. The empty pCMV-HA vector (1 µg) 
was used as a mock-transfected control.
Indirect immunofluorescence
Cells were washed three times with phosphate-buffered 
saline (PBS) and fixed in 100  % ethanol for 5  min at 
−20  °C. Fixed cells were washed with wash buffer (PBS 
containing 0.1 % sodium azide and 0.1 % BSA), and then 
incubated with anti-HBZ mAbs for 20 min at 4 °C. After 
washing with wash buffer, cells were incubated with an 
Alexa Fluor 488-conjugated secondary Ab (goat anti-
mouse IgG or goat anti-rat IgG; Cell Signaling Technol-
ogy). In parallel, the nuclei in the cells were also stained 
blue with 4′,6-diamidino-2-phenylindole (DAPI). Then, 
the cells were washed with PBS and mounted with 20 % 
glycerol (Merck). Slides were examined with a LSM700 
scanning laser confocal microscope (Carl Zeiss, Oberc-
ochen, Germany).
Flow cytometry
Cells were fixed and stained as described in the indirect 
immunofluorescence section. After incubation with sec-
ondary mAbs, the cells were washed and resuspended in 
wash buffer and analyzed by flow cytometry (FACSCanto 
II; BD Bioscience, San Jose, CA) with FlowJo software 
(Tomy Digital Biology, Tokyo, Japan).
Cell lysate preparation
Total proteins were extracted from uncultivated PBMCs 
or human T cell lines using Pierce RIPA Buffer (Thermo 
Fisher Scientific, Yokohama, Japan) with protease inhibi-
tor cocktail (Thermo Fisher Scientific). Briefly, 1  ×  107 
HTLV-1-infected and uninfected cells were washed three 
times with PBS, resuspended in Pierce RIPA Buffer with 
protease inhibitor cocktail, and then sonicated on ice 
using a Bioruptor® sonicator (Diagenode, Liège, Belgium) 
according to the manufacturer’s protocol. After centrifu-
gation (14,000×g, 4  °C, 15  min), the supernatants were 
collected for western blotting and sandwich ELISA.
Western blotting
Whole-cell lysates from HTLV-1-infected and uninfected 
cells were subjected to SDS-polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to polyvinylidene 
difluoride (PVDF) membranes (ATTO, Tokyo, Japan). 
PVDF membranes were blocked with 5  % skim milk in 
Tris-buffered saline containing 0.05  % Tween 20 (TBS-
T) and probed with anti-HBZ mAbs or anti-Histone H3 
mAb (Cell Signaling Technology, Danvers, MA). PVDF 
membranes were washed with TBS-T and incubated 
with horseradish peroxidase-conjugated secondary Abs 
(anti-rat IgG, HRP-linked whole Ab goat [NA935] or 
anti-mouse IgG, HRP-linked whole Ab sheep [NA931]; 
GE Healthcare, Buckinghamshire, England). After wash-
ing with TBS-T, the proteins were detected using Immu-
noStar LD (Wako) and visualized with a C-DiGit® Blot 
Scanner (LI-COR Biosciences, Lincoln, NE). To enhance 
the western blotting signals, Western BLoT Immuno 
Booster (Takara Bio, Shiga, Japan) was used according to 
the manufacturer’s protocol.
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Immunoprecipitation
The 293T cells in a 60 mm-diameter dish at 50 % conflu-
ence (6 ×  105 cells) were transfected with 3  μg of each 
indicated plasmids (i.e., pCMV-HA-HBZ or pCMV-HA-
empty) using Lipofectamine LTX (Thermo Fisher Scien-
tific, Waltham, MA) and then cultured for 24 h at 37 °C. 
The harvested cells were solubilized using lysis buffer 
(20 mM Tris–HCl [pH 7.9], 100 mM NaCl, 0.1 % Triton 
X-100). After sonication, homogenates were centrifu-
gated at 14,000×g at 4 °C for 5 min, and the supernatant 
fraction was used as extracts for assay. Then HA-tagged 
HBZ proteins were isolated by immunoprecipitation with 
each indicated anti-HBZ monoclonal antibody. Namely, 
monoclonal antibody was mixed and rotated at 4  °C for 
2 h with Protein A-Agarose Fast Flow (Sigma). The aga-
rose beads were washed two times with lysis buffer to 
remove unbound antibodies. Then, cell extracts were 
mixed and rotated at 4 °C for 2 h. The agarose beads were 
washed two times with lysis buffer, and immunoprecipi-
tated proteins were separated by 12  % SDS-PAGE, fol-
lowed by western blotting using anti-HA monoclonal 
antibody (Roche, 3F10).
Determination of HBZ‑specific antibody titers in the 
plasma and cerebrospinal fluid (CSF) of HTLV‑1‑infected 
individuals
HBZ-specific antibody titers in the plasma of HTLV-
1-infected individuals were determined by ELISA using a 
recombinant HBZ protein. Briefly, a 96-well flat-bottom 
plate (MaxiSorp; Nunc, Roskilde, Denmark) was coated 
with 50 µL of 1 µg/mL HBZ recombinant protein for 1 h 
at room temperature. Then, the wells were blocked with 
1 % skim milk in PBS with 0.05 % Tween 20 (PBS-T) at 
room temperature for 1 h. After washing three times with 
PBS-T, 50 µL of 1:100 diluted human plasma or undiluted 
CSF samples was added to each well, and the plate was 
incubated for 1 h at room temperature. We selected 1:100 
dilution of plasma in this ELISA, which showed the best 
performance (i.e., low background and high signal). After 
washing three times with PBS-T, 50  µL of HRP-conju-
gated goat anti-Human IgG F(ab′)2 (Jackson Immuno 
Research, West Grove, PA) was added to the wells, and 
the plate was incubated for 1  h at room temperature. 
After washing five times with PBS-T, 50 µL of SureBlue™ 
TMB Microwell Peroxidase Substrate (Kirkegaard & 
Perry Laboratories, Gaithersburg, MD) was added to the 
wells, and the plate was incubated for 5 min at room tem-
perature. The development reaction was stopped with 
50 µL of 2 M sulfuric acid (H2SO4), and then plates were 
read at 450 nm using a reference wavelength of 620 nm, 
with an automatic microplate reader (Multiskan™ FC; 
Thermo Fisher Scientific). Each sample was measured 
twice, and the results were determined by calculating 
the mean optical density (OD) for duplicate wells of each 
plasma sample. A positive result was defined as any value 
higher than the mean plus twice the standard deviation 
(SD) of the 17 NC samples (mean + 2SD = cut-off).
ELISA analysis of HBZ protein levels in PBMCs 
from HTLV‑1‑infected individuals
Whole-cell lysates were prepared as described in the 
Cell lysate preparation section. HBZ protein levels in cell 
lysates were evaluated by an in-house sandwich ELISA 
using mAbs against HBZ (i.e., clone #91-1 for capture and 
clone #20-H12 for detection) (Additional file  1: Figure 
S2). Briefly, a 96-well flat-bottom plate (Nunc) was coated 
with an anti-HBZ mAb (clone #91-1: rat IgG1 mAb raised 
against peptide #3) at 4  °C overnight, and then blocked 
with 5 % skim milk in PBS-T containing 0.05 % azide and 
0.05  % ProClin 30 (SIGMA) at room temperature for 
30 min, followed by three washes with PBS-T. Recombi-
nant HBZ was used as a standard and was diluted to a 
working concentration of 4000 ng/mL in antigen dilution 
buffer (PBS-T containing 0.1  % BSA, 0.05  % azide, and 
0.05 % ProClin 30). Subsequently, serial twofold dilutions 
of the standard were made to generate a series with con-
centrations ranging from 4 to 4000 ng/mL. Then, 50 μL 
of diluted standard or samples (i.e., 50 µg total cell lysates 
which is equal to the amount used in western blotting) 
was added to the plate, and the plate was incubated for 
1  h at room temperature. After washing the plate three 
times, 50 µL of diluted (0.2 µg/µL) HRP-conjugated anti-
HBZ mAb (clone #20-H12: mouse IgG1 mAb raised 
against peptide #2) was added as a detection antibody, 
and the plate was incubated for 1 h at room temperature 
along with solution-1 of Western BLoT Immuno Booster 
(Takara Bio). After washing the plates five times, 100 μL 
of TMB 1-Component Microwell Peroxidase Substrate, 
SureBlue (Kirkegaard & Perry Laboratories) was added to 
each well, and the plate was incubated for 5 min at room 
temperature. The development reaction was stopped 
with 50 µL of 2 M H2SO4, and then the plates were read 
at 450 nm using a reference wavelength of 620 nm, with 
an automatic microplate reader (Multiskan FC). The cut-
off value for the HBZ sandwich ELISA was calculated as 
the mean OD reading plus twice the standard deviation 
of four HTLV-1 uninfected cells (i.e., CEM, Jurkat, and 
two normal uninfected PBMCs). HRP was conjugated to 
the mAb using the Peroxidase labeling kit (DOJINDO, 
Kumamoto, Japan) according to the manufacturer’s 
protocol.
Genomic DNA and RNA extraction and cDNA synthesis
Genomic DNA was extracted from PBMCs using the 
QIAamp blood kit (QIAGEN, Tokyo, Japan). RNA was 
extracted from PBMCs using the RNeasy Mini Kit with 
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on-column DNase digestion (QIAGEN, Hilden, Ger-
many). Complementary DNA (cDNA) was synthesized 
using the PrimeScript® RT reagent Kit (Takara Bio). 
All procedures were performed as suggested by the 
manufacturer.
Quantification of HTLV‑1 PVL
To measure the HTLV-1 PVL in PBMCs, we used a 
quantitative PCR method with 100 ng of genomic DNA 
(roughly equivalent to 104 PBMCs) and the ABI 7500 
Fast Real-Time PCR System (Applied Biosystems, Fos-
ter City, CA). We used β-actin gene for normalization of 
PVL per cell. Namely, since single PBMC has two cop-
ies of β-actin, the HTLV-1 PVL was determined using 
the following formula: HTLV-1 tax copy number per 
1  ×  104 PBMCs  =  [(tax copy number)/(β-actin copy 
number/2)]  ×  104. Further details of this mothod are 
given in previous work [15]. All samples were analyzed in 
triplicate.
Real‑time RT‑PCR analysis
We performed TaqMan® real-time RT-PCR assays to 
determine the quantitative differences in the expres-
sion of HBZ mRNA as previously reported [8]. In real-
time RT-PCR analysis, we detected the spliced isoform 
of HBZ, which is the most abundant HBZ transcript 
and significantly contributes to HBZ protein synthesis 
[22–24]. HBZ mRNA expression were normalized to 
the expression of the hypoxanthine ribosyl transferase 
(HPRT) gene (Human HPRT1 Endogenous Control 
4333768; Applied Biosystems). Namely, serially diluted 
cDNA from HTLV-1 infected MT-2 cells was used for 
generating standard curves for the value of HBZ mRNA 
and HPRT mRNA, and the relative HBZ mRNA load 
was calculated by the following formula: HBZ mRNA 
load  =  value of HBZ/value of HPRT. Further details of 
this mothod are given in previous work [8].
Statistical analysis
The Mann–Whitney U test was used to compare data 
between two groups. Correlations between variables were 
examined using Spearman’s rank correlation analysis. The 
results shown are the mean ± SD where applicable. P val-
ues less than 0.05 were considered statistically significant.
Results
Development of mAbs against HBZ
We established seven hybridoma clones secreting HBZ-
reactive IgG antibodies (Additional file  2: Table S1). 
These antibodies were examined for antigen specificity, 
HBZ expression, and HBZ localization after purification. 
Antibody reactivity and specificity were confirmed by the 
detection of HBZ protein in the cell extracts of 293T cells 
transfected with the HBZ expression plasmid pCMV-
HA-HBZ, but not in extracts from mock-transfected cells 
(transfected with pCMV-HA-Mock; Fig.  1). As previ-
ously reported [5], indirect immunofluorescence of 293T 
cells transfected with an HBZ expression plasmid showed 
a granular distribution of HBZ protein in the nucleus 
(Fig. 1a). Western blotting of 293T cells transfected with 
the HBZ expression plasmid showed a single prominent 
band of the predicted length for full-length HBZ protein 
(31  kDa), whereas mock-transfected 293T cells did not 
show any bands (Fig.  1b). We also attempted to detect 
HBZ protein by flow cytometry (Fig.  1c). As shown in 
Fig.  1c, 293T cells transfected with the HBZ expression 
plasmid were specifically stained with the anti-HBZ 
mAbs, whereas mock-transfected cells were not. These 
results confirm the specificity of our mAbs against HBZ 
protein, and demonstrate that they can be used for intra-
cellular flow cytometric analysis.
The expression of endogenous HBZ protein 
in HTLV‑1‑infected cell lines
To confirm the expression and localization of HBZ in 
chronically infected cells, we performed western blotting 
and indirect immunofluorescence staining of naturally 
HTLV-1-infected T cell lines (Fig. 2a, b). Among the four 
anti-HBZ monoclonal antibodies (i.e., P6-A7, #20-H12, 
#91-1, #7-1) tested, #91-1 and #7-1 antibodies are suit-
able for western blotting, and #91-1 provides the great-
est sensitivity (Additional file 1: Figure S3). As shown in 
Fig. 2a, western blotting with #91-1 raised against peptide 
#3 (rat IgG1) showed that the HBZ protein was expressed 
in all the HTLV-1-infected T cell lines examined, but was 
not detected in non-infected T cell lines (Fig. 2a). Inter-
estingly, in the HTLV-1-infected T cell line MT-1, the 
HBZ protein was a lower molecular weight than in the 
other infected cell lines. Since sequence analysis revealed 
that the coding sequence of the HBZ gene in MT-1 cells 
is completely conserved (data not shown), it is supposed 
that post transcriptional regulation of HBZ protein may 
be the cause of this observation. We also examined HBZ 
in the HTLV-1-infected T cell lines by immunofluores-
cence with our mAb raised against recombinant HBZ 
(clone #7-1, mouse IgG2b), which provides the greatest 
sensitivity (Fig.  2b). As shown, the HTLV-1-infected T 
cell lines MT-1 and SLB1 exhibited a granular nuclear 
distribution, as was observed in the 293T cells trans-
fected with the HBZ expression plasmid, whereas the 
HTLV-1 uninfected T cell line CEM did not. We further 
investigated whether our in-house mAbs against HBZ is 
suitable for immunoprecipitation. As shown in Fig.  2c, 
among the four anti-HBZ mAbs tested (P6-A7, #20-H12, 
#91-1, #7-1), P6-A7, #20-H12, and #7-1 were available for 
immunoprecipitation.
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Detection of anti‑HBZ antibodies in some plasma samples 
from HTLV‑1‑infected individuals with different clinical 
status
To investigate the relationship between the expression 
level of HBZ mRNA and the antibody response against 
HBZ in Japanese HTLV-1-infected individuals with dif-
ferent clinical status (i.e., HAM/TSP, ATL, and AC), 
we quantified the expression of HBZ mRNA in PBMCs 
and anti-HBZ Abs in plasma. First, using plasma sam-
ples from 210 HTLV-1-infected individuals (48 ACs, 42 
patients with ATL, and 120 patients with HAM/TSP), we 
evaluated plasma anti-HBZ Abs by ELISA with a recom-
binant HBZ protein. These data were then compared 
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Fig. 1 Generation and characterization of anti-HTLV-1 bZIP factor (HBZ) monoclonal antibodies (mAbs). a HBZ protein levels in HBZ-transfected 
293T cells were analyzed by indirect immunofluorescence using anti-HBZ mAbs P6-A7 (raised against peptide #1, mouse IgG2b), #20-H12 (raised 
against peptide #2, mouse IgG1), #91-1 (raised against peptide #3, rat IgG1), and #7-1 (raised against recombinant HBZ, mouse IgG2b). b HBZ 
expression vector-transfected 293T cells (HBZ) and mock-transfected 293T cells (Mock) were analyzed by western blotting using the novel anti-HBZ 
mAbs. c HBZ expression vector-transfected 293T cells (red line) and mock-transfected 293T cells (blue line) were analyzed by flow cytometry using 
the novel anti-HBZ mAbs. Three independent experiments were performed, and representative data are shown in each figure
















Fig. 2 HBZ protein expression in HTLV-1-infected cell lines. a HBZ protein expression in HTLV-1-infected cell lines was analyzed by western blotting 
using anti-HBZ mAb #91-1 (raised against peptide #3, rat IgG1), which gave highest sensitivity among four mAbs (i.e. P6-A7, #20-H12, #91-1, #7-1). 
Histone H3 was used as a loading control for the nuclear fraction. b HBZ protein expression in HTLV-1-infected cell lines (MT-1 and SLB1) was ana-
lyzed by immunofluorescence microscopy using anti-HBZ mAb #7-1 (raised against recombinant HBZ, mouse IgG2b), which gave highest sensitivity 
among four mAbs (i.e. P6-A7, #20-H12, #91-1, #7-1). Three independent experiments were performed, and representative data are shown in each 
figure. c Immunoprecipitation assay using four different anti-HBZ mAbs. P6-A7, #20-H12, and #7-1 were available for immunoprecipitation
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in Fig.  3, immunoreactivity against HBZ was detected 
only in 10.4 % (5/48) of ACs, 10.8 % (13/120) of patients 
with HAM/TSP, and 16.7 % (7/42) of patients with ATL. 
Although a high titer of anti-HBZ antibody was detected 
in the plasma of certain patients with HAM/TSP, there 
was no statistically significant difference among the three 
groups. In these anti-HBZ antibody-positive individu-
als, the antibody response to HBZ did not correlate with 
HBZ mRNA expression, except in ACs (Fig. 4a), and the 
antibody response to HBZ did not correlate with the 
PVL in any of the test groups (Fig. 4b). This observation 
is consistent with a previous study, which also demon-
strated that antibody responses against HBZ did not cor-
relate with HBZ mRNA expression or PVL in patients 
with HAM/TSP [25]. Next, we examined the antibody 
responses against HBZ in CSF, since strong antibody 
responses against HTLV-1 antigens other than HBZ have 
been reported in the CSF of HAM/TSP patients [26, 27]. 
However, antibodies against HBZ were not detected in 
any of the CSF samples examined (0 out of 120, data not 
shown).
Detection of HBZ proteins in the PBMCs of ATL patients 
but not in HAM/TSP patients or ACs
To determine the absolute intracellular concentration 
of HBZ protein in naturally HTLV-1-infected cells, we 
developed a sandwich ELISA using our in-house anti-
HBZ mAbs (Additional file  1: Figure S2). Recombi-
nant HBZ was used as a standard. Western blot images 
of twofold serially diluted recombinant HBZ probed 
with an anti-HBZ mAb (clone #91-1) and a representa-
tive standard curve for the ELISA are shown in Fig.  5a, 
b, respectively. Using this system, we report the absolute 
quantification of HBZ protein in HTLV-1-infected cells. 
Although the levels of HBZ detected by ELISA match the 
levels of HBZ from western blotting when we quantify 
the intensity of HBZ band relative to Histone H3 in each 
sample by ImageJ software (data not shown), HBZ pro-
tein and mRNA levels were not correlated in HTLV-1-in-
fected T cell lines (Fig. 5c). As shown in Fig. 5a, #91-1 can 
detect at least 1 ng of HBZ protein by western blotting. 
In the recent report by Raval et  al. [28], their anti-HBZ 
mAb 4D4-F3 could detect at least 2 ng of purified GST-
tagged HBZ protein, indicating nearly equivalent sensi-
tivity to #91-1. We further examined the expression levels 
of HBZ protein in the PBMCs of HTLV-1-infected indi-
viduals with different clinical status, and the data were 
compared to both HBZ mRNA levels and PVL (Addi-
tional file 2: Table S2; Fig. 6). HBZ protein was detected 
in three out of five acute ATL patients examined, but was 
not detected in any HAM/TSP patients (zero out of ten) 
or ACs (zero out of four) (Fig. 6a). Further, the HBZ pro-
tein data were compared to anti-HBZ antibody levels in 
plasma (Fig. 6b), HBZ mRNA levels in PBMCs (Fig. 6c), 
and PVL levels in PBMCs (Fig.  6d). We observed that 
the amount of HBZ protein in primary HTLV-1-infected 
cells was correlated with PVL but not with either anti-
HBZ antibody or HBZ mRNA levels. 
Discussion
HBZ has been reported to play important roles in the 
pathogenesis of both ATL and HAM/TSP. However, to 
date, there is no report of a comprehensive analysis of 
HBZ mRNA and protein expression, anti-HBZ Ab levels, 
and HTLV-1 PVL in patients with ATL and HAM/TSP as 
well as ACs. To further our understanding of HTLV-1-as-
sociated diseases and to aid in the development of new 
therapies, it is important to evaluate the expression pro-
files of HBZ and the host immune response against HBZ 
using samples from HTLV-1-infected patients with differ-
ent clinical status. In particular, direct analysis of native, 
endogenous HBZ protein is crucial. In this study, we 
developed new mAbs specific for HBZ that can be used 
for flow cytometry, western blotting, ELISA, and immu-
nofluorescence microscopy. We observed the expression 
and localization of native, endogenous HBZ protein in 
HTLV-1-infected human T cells. Our results are con-
sistent with previous observations that HBZ protein was 
expressed in all HTLV-1-infected T cell lines examined 
and is localized to the nucleus, with a speckle-like distri-
bution [28]. Similar results were observed in cells over-
































Fig. 3 Detection of HBZ-specific antibodies in the plasma of HTLV-
1-infected individuals with different clinical status. Antibodies against 
HBZ in plasma samples from HTLV-1-infected individuals were 
detected by ELISA using a recombinant HBZ protein as the coating 
antigen. Each plasma sample (50 µL of a 1:100 dilution) was exam-
ined twice, and the results shown are the mean optical density (OD) 
of duplicate wells. A positive result was any value higher than the 
mean OD plus twice the standard deviation (dotted line represents 
the cut-off value) of the 17 NC plasma samples. Differences between 
groups were analyzed with the Mann–Whitney U test
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this subcellular localization of HBZ protein is not due to 
overexpression or non-physiological conditions. A recent 
report by Raval et al. showed that native HBZ protein in 
the nucleus co-localizes with many transcriptional regu-
lators, such as p300, JunD, CBP, and CREB2 [28]. Molec-
ular analyses, such as chromatin immunoprecipitation, 
may identify a large set of HBZ-targeted genes, which 
might be involved in the pathogenesis of HTLV-1-associ-
ated diseases. Since our mAbs P6-A7, #20-H12, and #7-1 
were available for immunoprecipitation, these mAbs may 
be useful tools for future functional studies for HTLV-1 
and its associated diseases.
Recently, two studies suggested the existence of anti-
HBZ antibodies in HTLV-1-infected individuals [25, 31]. 
Enose-Akahata et  al. reported the antibody responses 
against HBZ in US-resident patients with HAM/TSP 
of mainly African descent [25]. Furuta et  al. found one 
blood donor with antibodies against HBZ among 114 
HTLV-1-positive plasma samples from Japanese Red 
Cross blood centers (0.88 %) in Japan; these samples were 
assumed to be from ACs [31]. Using our HBZ-specific 
ELISA, we screened 210 plasma samples, including 48 
from ACs, 120 from HAM/TSP patients, and 42 from 
ATL patients, for immunoreactivity against HBZ, and 
the results were compared to both the HBZ mRNA levels 
and the PVL in PBMCs of these HTLV-1-infected indi-
viduals. Anti-HBZ antibodies were detected in 10.4  % 
(5/48) of ACs, 10.8 % (13/120) of HAM/TSP, and 16.7 % 
(7/42) of ATL patients in our Japanese samples. These 













































































































































































HBZ plasma Abs titer 
(Absorbance at 450 nm)
HBZ plasma Abs titer 
(Absorbance at 450 nm)










































Fig. 4 Correlation analysis between plasma anti-HBZ antibody levels and HTLV-1 mRNA levels or proviral load in HTLV-1-infected individuals. a 
HTLV-1 HBZ mRNA levels were significantly correlated with plasma anti-HBZ antibody levels in ACs (p = 0.0093, r = 0.477), but not in HAM/TSP 
patients (p = 0.974, r = −0.003) or ATL patients (p = 0.141, r = −0.234) by Spearman’s rank correlation analysis. b HTLV-1 HBZ mRNA levels were 
not significantly correlated with HTLV-1 PVL in ACs (p = 0.964, r = 0.0068), HAM/TSP patients (p = 0.152, r = 0.132), and ATL patients (p = 0.953, 
r = 0.0095). Correlations were examined by Spearman’s rank correlation analysis. The dotted line represents the cut-off, i.e. the mean OD plus twice 
the standard deviation of the 17 NC plasma samples
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that anti-HBZ antibody was detected in 10.34 % (15/145) 
of ACs, 13.46  % (14/104) of HAM/TSP patients, and 
12.36 % (11/89) of ATL patients [25]. In addition, consist-
ent with this US study, our data showed that the antibody 
responses against HBZ were not correlated with PVL or 
HBZ mRNA expression in HAM/TSP patients. We also 
examined the antibody responses against HBZ in the 
CSF of HAM/TSP patients. Although the previous study 
showed HBZ-specific antibody responses in the CSF in 
two out of five patients examined, albeit at lower levels 
than in serum, we did not detect antibodies against HBZ 
in any of the 120 CSF samples examined. We conclude 
that HBZ-specific antibody responses in CSF of HAM/
TSP patients were significantly weaker than the response 
to other HTLV-1 antigens such as Gag, Env and Tax, 
because antibody responses against these molecules can 
be found in both serum and CSF; in certain patients the 
titers are higher in CSF than in plasma [25]. These find-
ings indicate that the frequency of antibody responses 
to HBZ was surprisingly low compared to antibody 
responses to other viral proteins such as Gag, Env and 

































































































































Fig. 5 Quantification of HBZ protein expression levels in HTLV-1-infected T-cell lines. The absolute intracellular concentration of an endogenous 
HBZ protein in HTLV-1-infected T-cell lines was analyzed by a novel HBZ sandwich ELISA. a Western blot image of twofold serially diluted recombi-
nant HBZ protein probed with anti-HBZ mAb (clone #91-1). b A representative standard curve for the ELISA comprised of twofold serial dilutions of 
recombinant HBZ protein (from 4000 to 3.91 ng/mL). c Absolute quantification of HBZ protein in HTLV-1-infected T-cell lines. Results are presented 
as mean ± SD of three independent experiments with duplicate wells








































































































































































































































































































































































Fig. 6 Quantification of HBZ protein expression levels and comparison to HBZ mRNA load, anti-HBZ antibody levels, and PVL in clinical samples 
from HTLV-1-infected individuals with different clinical status. a HBZ protein expression levels in naturally infected PBMCs of HTLV-1-infected 
individuals with different clinical status, evaluated by an in-house sandwich ELISA using mAbs against HBZ. HBZ protein was detected in three out 
of five acute ATL patients examined, but not in HAM/TSP patients (zero out of ten) or ACs (zero out of four). The dotted line represents the cutoff, 
i.e. the mean OD plus twice the standard deviation of four HTLV-1 uninfected cells (CEM, Jurkat, and two normal uninfected PBMCs). b Anti-HBZ 
antibody levels in plasma of HTLV-1-infected individuals with different clinical status determined by ELISA using a recombinant HBZ protein. c HBZ 
mRNA levels in PBMCs of HTLV-1-infected individuals with different clinical status determined by real-time PCR. HBZ mRNA expression were normal-
ized to the expression of the hypoxanthine phosphoribosyltransferase gene (Human HPRT1 Endogenous Control 4333768; Applied Biosystems). d 
HTLV-1 proviral load (PVL) in PBMCs of HTLV-1-infected individuals with different clinical status. The HTLV-1 PVL was determined using the following 
formula: HTLV-1 tax copy number per 1 × 104 PBMCs = [(tax copy number)/(β-actin copy number/2)] × 104. All samples were analyzed in triplicate
Page 12 of 14Shiohama et al. Retrovirology  (2016) 13:29 
is probably due to the low immunogenicity of HBZ or the 
low sensitivity of the method used. In any case, it is clear 
that antibody responses to HBZ can be detected in a 
proportion of individuals in vivo in the course of natural 
HTLV-1 infection, with similar frequencies in two ethni-
cally diverse HTLV-1-infected populations (i.e. Japanese 
and American of mainly African descent), which carry 
different subgroups of HTLV-1 [25]. It is noteworthy 
that in human immunodeficiency virus (HIV) infection, 
antibody responses against the viral transcription factor 
Tat, which plays an important role in viral infectivity and 
pathogenicity, are also detected only in a small propor-
tion of HIV-infected individuals (30 out of 252 subjects, 
11.9 %) [34]. Since the presence of anti-Tat antibodies is 
associated with delayed disease progression [34, 35], it 
will be interesting to see whether the presence of anti-
HBZ antibodies is associated with the clinical course of 
HTLV-1-associated diseases. However, we did not find 
any significant relationship between the presence of anti-
HBZ antibodies and disease progression in HAM/TSP 
patients (data not shown). In addition, neither the pre-
vious study nor our current study showed a significant 
association between the frequency of a humoral immune 
response to HBZ and the clinical status of HTLV-1 infec-
tion (i.e., HAM/TSP, ACs, and ATL) [25]. In contrast, 
although the previous study showed a significant differ-
ence in the HBZ-specific antibody responses between 
ATL patients with chronic and lymphoma subtypes 
[25], we did not observe any significant differences in 
the HBZ-specific antibody responses among the differ-
ent clinical subtypes of ATL (data not shown). Although 
further studies are needed to clarify the reason for this 
difference, it is possible that both the viral subgroup and 
host genetic background (including HLA type) determine 
the anti-HBZ antibody response, since our recent study 
indicated that different HTLV-1 subgroups are character-
ized by different patterns of viral and host gene expres-
sion in HAM/TSP patients via independent mechanisms 
of direct transcriptional regulation [36].
In this study, using a sandwich ELISA based on two 
novel in-house mAbs, we report the absolute quantifica-
tion of HBZ protein in naturally HTLV-1-infected cells. 
The amount of endogenous HBZ protein varied between 
76.9 and 371.4  ng/mL in HTLV-1-infected T cell lines 
and between 64.2 and 96.4 ng/mL in the primary PBMCs 
of ATL patients, which was two- to tenfold less than the 
amount overexpressed in HBZ-transfected 293T cells. 
HBZ protein was detected only in a proportion of the 
PBMCs from acute ATL patients, and was not detected 
in the PBMCs from HAM/TSP patients or ACs. Our data 
also indicate that the expression levels of HBZ mRNA 
were not correlated with HBZ protein levels. However, 
interestingly, our data show that the amount of HBZ 
protein in primary HTLV-1-infected cells was correlated 
with PVL. One possible explanation for the discrepancy 
in expression levels between HBZ protein and mRNA is 
that HBZ RNA and protein may have distinct functions. 
A previous report by Satou et  al. showed that a mutant 
HBZ without the first ATG codon (required for transla-
tion) still promoted T cell proliferation but did not sup-
press HTLV-1 transcription, whereas a missense HBZ 
mutant that possibly disrupted the RNA secondary struc-
ture did not promote T cell proliferation [7]. Namely, the 
activation and polyclonal proliferation of HTLV-1-in-
fected cells, which is closely related to HAM/TSP patho-
genesis, may depend on HBZ RNA structure rather than 
on HBZ protein. Indeed, we previously reported that 
HBZ mRNA is constitutively expressed in the PBMCs of 
all HAM/TSP patients, and that HBZ mRNA expression 
in HTLV-1-infected cells was decreased after successful 
immunomodulatory treatment for HAM/TSP [8]. Fur-
thermore, a recent report by Mitobe et al. provided evi-
dence that HBZ RNA associates with genes involved in 
the cell cycle and cell proliferation and survival, whereas 
HBZ protein is more closely related to the immunologi-
cal properties of T cells [37]. It may be possible that the 
most important actions of HBZ, which are critical to 
HTLV-1 persistence, are exerted at the RNA level, and 
not the protein level. Another possibility is that HTLV-1 
may have evolved to minimize HBZ translation. Conse-
quently, HBZ protein suppress the translation efficiency 
of HBZ itself. This hypothesis may be supported by the 
findings that HBZ is an important target of the T cell 
response [13, 14] and most HBZ mRNA and protein is 
retained in the nucleus [38].
Meanwhile, although both HBZ protein expression 
and immune responses against HBZ were extremely low 
in  vivo, recent studies demonstrated the importance 
of the in  vivo functions of the HBZ protein. Namely, a 
recent in silico analysis showed that efficient CTL recog-
nition and a strong immune response to HBZ is impor-
tant for efficient control of viral replication [13], which 
reduces the risk of HTLV-1-associated diseases in HTLV-
1-infected individuals [15, 16]. Also, it has recently been 
reported that HBZ-targeted vaccination by recombi-
nant vaccinia viruses could induce CTLs, which have an 
anti-lymphoma effect in mouse and macaque models of 
ATL, suggesting the potential of HBZ as a target antigen 
for immunotherapy [18]. These results demonstrated 
the potentially beneficial roles of HBZ-specific immune 
responses against HTLV-1-associated diseases and the 
importance of HBZ protein.
Since transgenic expression of HBZ in CD4+ T cells 
induced both T-cell lymphoma and systemic inflamma-
tion in mice [10], it is clear that HBZ protein is also criti-
cal for the development of HTLV-1-associated diseases. 
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Our present data suggest the possibility that the low but 
distinct expression of HBZ protein in the PBMCs of ATL 
patients along with the increased number of infected 
cells may be associated with the development of ATL. 
Therefore, targeted immunotherapy against HBZ may be 
effective for the clearance of HTLV-1-infected cells and 
the prevention of HTLV-1-associated diseases.
Conclusions
In summary, we demonstrated the absolute quantifica-
tion of HBZ protein in naturally HTLV-1-infected cells 
of ATL patients. The very low immunogenicity of HBZ in 
HTLV-1-infected individuals, which may be due to mini-
mized HBZ protein translation, is a sophisticated viral 
strategy for evasion from the host T cell response, result-
ing in the survival of HTLV-1-infected cells and conse-
quent pathogenesis of HTLV-1-related disorders.
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